Becton, Dickinson and Company $BDX Position Reduced by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.8% in the third quarter, HoldingsChannel reports. The fund owned 679,261 shares of the medical instruments supplier’s stock after selling 26,852 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Becton, Dickinson and Company were worth $121,588,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in BDX. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $3,721,533,000. State Street Corp lifted its position in shares of Becton, Dickinson and Company by 8.5% in the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares in the last quarter. Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the second quarter worth $474,993,000. Finally, Legal & General Group Plc boosted its holdings in Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock worth $318,050,000 after purchasing an additional 30,766 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Trading Up 0.4%

Shares of Becton, Dickinson and Company stock opened at $198.77 on Tuesday. The stock has a market cap of $54.77 billion, a P/E ratio of 59.87, a P/E/G ratio of 13.16 and a beta of 0.21. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $200.47. The business’s 50 day moving average is $186.71 and its 200-day moving average is $170.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the business earned $3.68 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on BDX shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Wolfe Research initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Finally, Barclays initiated coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.